Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Set Alert for Commercial

Killing Targeted Bacteria With CRISPR Drugs Is SNIPR BIOME's Promise

SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.

Clinical Trials Infectious Diseases Gastrointestinal

Vasopharm Sees Path Forward For Traumatic Brain Injury Drug

Vasopharm’s ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma, suggesting a role for the compound in the condition.

Neurology Clinical Trials Research & Development

Companies

Set Alert for Companies

Latest From Companies

Long-Term Data Boost Novartis And Roche SMA Challenge To Biogen’s Spinraza

New long-term data from Novartis’s Zolgensma and Roche’s Erysdi will help close the gap on Biogen’s market leader Spinraza, but the three therapies look set to develop distinct or even complementary roles as the market matures.

Commercial Companies

Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse

The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.

Deals Companies

Stock Watch: The Transatlantic Asymmetries Of Generic Drugs

Investors love an opportunity to invest in a recovery play after the disclosure of bad news but, having lived in recent years under a succession of clouds, will generic drug companies begin to see biosimilars resurrect their sales growth?

Stock Watch Companies

Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa

The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.

Clinical Trials Companies

Obstacle Thrown In Sarepta’s Path To Market As Gene Therapy Will Face AdComm After All

The route to market for Sarepta’s gene therapy candidate SRP-9001 for Duchenne muscular dystrophy has just got more complex after a U-turn by the US FDA. Its accelerated approval will now be scrutinized by outside experts – but the company remains confident in its data.

Companies Neurology

Another Blow For Anti-TIGITs As Merck’s Vibostolimab/Keytruda Combo Misses In Phase II NSCLC Trial

Merck & Co’s combination treatment has disappointed in a challenging group of lung cancer patients, marking yet another setback for the increasingly precarious anti-TIGIT space even as some analysts say this is not the end of the road.

Clinical Trials Companies
See All

Deals

Set Alert for Deals

Latest From Deals

Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse

The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.

Deals Companies

Pharma Giants Urge Biotechs To Get In Touch As Early As Possible

Although money is too tight to mention for some biotechs, last year the value of preclinical partnerships actually went up and Switzerland’s big two pharma players are on the lookout for more.

Deals StartUps and SMEs

Chinese Biotech Expects Limited Impact From SVB Aftermath

Favored by venture capital funds, Silicon Valley Bank has served biotech firms conducting transactions in the US. But its collapse is generating a ripple effect on Chinese start-ups already hard hit by a funding crunch.

China Financing

MorphoSys Pins Hopes On Pelabresib For Near-Term Value After Tumultuous 2022

The German biotech has highlighted its myelofibrosis drug candidate, pelabresib, as a key value driver going forward after a year of hard knocks and lackluster Monjuvi sales that forced the firm to downsize its workforce and cease preclinical operations.

Cancer Sales & Earnings

The Eyes Still Have It For Novartis Despite Sell-Off Rumors

Rumors have resurfaced that Novartis is looking to shift some of its eye drugs but the Basle-based behemoth tells Scrip it remains committed to in-market products and R&D projects in the ophthalmology space.

Ophthalmic Restructuring

Stock Watch: Funding Biotech In A Hostile Environment

When the traditional fundraising window closes and clinical, regulatory or commercial success eludes, other routes to raise cash emerge. But these have also become more scarce recently, leaving all-stock consolidations.

Stock Watch Financing
See All

Strategy

Set Alert for Strategy

Latest From Strategy

COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says

CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.

China Vaccines

AstraZeneca And Huma On Digital’s Value For Pharma

Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.

Artificial Intelligence Digital Health

Servier’s Oncology Strategy Pays Off As Vorasidenib Hits Bullseye In Pivotal Glioma Trial

The French firm’s vorasidenib, obtained via a 2020 deal with Agios, has met the primary endpoint in a pivotal glioma trial, according to interim data, validating its strategic focus on the oncology space.

Clinical Trials Cancer

Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024

Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.

Strategy Dermatology

Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success

Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.

Clinical Trials Cardiovascular

Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.

Deals M & A
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients

Sanofi is the last of three big insulin makers to offer its top-selling insulin at the same out-of-pocket cost regardless of patients’ insurance coverage, but calls for other health care players to make concessions as well.

Market Access Pricing Strategies

Both Pfizer And GSK RSV Vaccines Set For Approval – But Could Next Readouts Give One The Edge?

The two frontrunners look set to gain US FDA approval, but will need more robust long-term data to convince frontline physicians and payers of benefits to at-risk individuals.

Advisory Committees Commercial

‘Inertia’ Likely To Restrain Biosimilar Humira In US Market, Experts Say

PBM contracting and payer formulary placement for branded Humira signal headwinds for biosimilar versions in the US, according to participants in an IQVIA-sponsored panel.

Biosimilars Market Access
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends

From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.

Scrip Asks Clinical Trials

Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence

The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.

Scrip Asks Artificial Intelligence

Pfizer’s COVID-19 Franchise Dominates Best-Seller List

Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.

Scrip Perspectives Market Intelligence
See All
UsernamePublicRestriction

Register